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OBJECTIVES We sought to determine the impact of aggressive stent expansion on creatine kinase-MB
isoenzyme (CK-MB) release and clinical restenosis.
BACKGROUND Elevation of CK-MB after percutaneous coronary interventions has been associated with late
mortality.
METHODS We identified 989 consecutive patients who underwent intravascular ultrasound-guided
stenting of 1,015 coronary lesions. Patients were divided into three groups according to stent
expansion, defined as the ratio of final lumen over the reference lumen cross-sectional areas:
Group 1 (ratio 70%, n  117 patients with 126 lesions); Group 2 (ratio 70% to 100%, n
 551 patients with 562 lesions); Group 3 (ratio100%, n 321 patients with 327 lesions).
RESULTS The peak CK-MB values increased significantly with increasing stent expansion: CK-MB 
3 to 5 normal occurred 16%, 18%, and 25% in Groups 1, 2, and 3, respectively, p  0.02;
CK-MB 5 times normal occurred 9%, 13%, and 16% respectively, p  0.02. Conversely, at
one year follow-up there was a stepwise decrease in target lesion revascularization (11% vs.
19% and 17%, respectively, p  0.04) and major adverse cardiac events with increasing stent
expansion. In addition, there was a trend toward lower mortality in Group 3 (9% vs. 4.4% vs.
4.0%, p  0.07).
CONCLUSIONS Intravascular ultrasound-guided stent overexpansion (final lumen greater than reference
lumen cross-sectional area) is accompanied by a higher periprocedural CK-MB release but a
lower target lesion revascularization and a trend toward lower mortality at one year. Increased
periprocedural CK-MB release appears as a trade-off for optimal stent implantation and lower
clinical restenosis. (J Am Coll Cardiol 2003;42:1900–5) © 2003 by the American College
of Cardiology Foundation
Percutaneous interventional techniques continue to evolve,
including optimization of stent implantation. The final
lumen dimension achieved after stenting is one of the most
powerful predictors of restenosis (1–3). Even though rou-
tine high-pressure balloon inflation affords a better lumen at
the end of the intervention, its systematic use during
coronary stent placement has not been associated with
significant improvement in one-year outcome (4). On the
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contrary, routine high-pressure inflation may be accompa-
nied by a higher creatine kinase-MB isoenzyme (CK-MB)
elevation (4). We have previously shown that CK-MB
elevation after percutaneous coronary intervention (PCI) is
associated with an increased atherosclerotic plaque burden
and calcification (5); it occurs after 6% to 30% of otherwise
successful PCI (6,7) and may be associated with increased
late mortality (8,9).
Several intravascular ultrasound (IVUS) criteria have
been used to optimize stent expansion in an attempt to
reduce clinical and angiographic restenosis. The purpose of
the current study was to determine the relationship between
stent expansion, as assessed by IVUS, and both post-PCI
CK-MB elevation and clinical restenosis.
METHODS
Patient population. The Cardiovascular Research Foun-
dation Database was queried to identify 989 consecutive
patients who underwent IVUS-guided stenting of 1,015
native coronary lesions between January 1994 and June
1999. Patients with acute myocardial infarction (MI), pre-
PCI elevation, and restenotic lesions were excluded. Events
were recorded at 30-day and one-year clinical follow-up.
Patients were divided into three groups according to stent
expansion, defined as a ratio represented by the final lumen
divided by the reference lumen cross-sectional area (CSA):
Group 1 (stent expansion ratio 70%) with 117 patients
and 126 lesions; Group 2 (ratio 70% to 100%) with 551
patients and 562 lesions; and Group 3 (ratio 100%) with
321 patients and 327 lesions. Stents were used for elective
indications, suboptimal angioplasty results, and abrupt or
threatened closure.
Procedures. All procedures were performed after written
informed consent. All patients underwent PCI according to
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current stent-implantation guidelines and techniques (10).
All patients received aspirin 325 mg daily at least 24 h
before the procedure and indefinitely afterwards. Patients
were treated concomitantly with a thienopyridine: either
ticlopidine 250 mg twice daily or clopidogrel 75 mg daily for
four weeks. Weight-adjusted heparin was administered
during the procedure and was routinely discontinued at the
end of the procedure. Platelet glycoprotein IIb/IIIa inhibi-
tors were used in 4% of cases.
Angiographic analysis. Cineangiograms were analyzed us-
ing a validated system (ARTEK, Quantitative Cardiac
Systems, Ann Arbor, Michigan) by a dedicated core labo-
ratory blinded to the IVUS and clinical data. Using the
contrast-filled catheter as the calibration standard, minimal
lumen diameter, reference diameter, and percent diameter
stenosis before and after PCI were obtained from the single
“worst” and least foreshortened view. The reference segment
diameter was averaged from user-defined, 5-mm-long an-
giographically normal segments proximal and distal to the
stenosis in the projection with the least amount of fore-
shortening. Ostial lesions were within 3 mm of the coronary
ostia or 3 mm distal to a major proximal side branch.
These are standard qualitative and quantitative analyses and
definitions, and they have been published previously (11).
IVUS imaging and analysis. Intravascular ultrasound im-
aging was performed after administration of 0.2 mg of
intracoronary nitroglycerin, using a system made by one
of the following manufacturers: CVIS/Inter Therapy,
Hewlett-Packard and Boston Scientific Corporation, or
Cardiovascular Imaging Systems/Boston Scientific Corpo-
ration. The IVUS catheter was advanced approximately 10
mm distal to the lesion, the video recorder was turned on,
the transducer and pullback device was activated, and the
entire artery was imaged and recorded on 0.5-inch high-
resolution s-VHS for off-line analysis.
Validations of normal coronary anatomy, plaque compo-
sition, and measurements using IVUS have been reported
(12). Using computer planimetry (TapeMeasure, Indec
Systems), the following lesion and reference measurements
were made in diastole (13,14). The external elastic mem-
brane (EEM) CSA was measured by tracing the leading
edge of the adventitia. The lesion site was the cross-
sectional slice with the smallest lumen; among sections with
the same lumen area, the one with the most plaque was
Table 1. Patient Demographic and Lesion Characteristics
Stent Expansion Ratio
Group 1
<70%
Group 2
70%–100%
Group 3
>100% p Value
Patients n  117 n  551 n  321
Age (yrs) 63  11 62  12 63  11 0.7
Male gender (%) 68 72 65 0.05
Unstable angina (%) 29 27 27 0.9
Hypertension (%) 60 59 62 0.7
Hypercholesterolemia (%) 70 66 65 0.5
Diabetes (%) 30 28 30 0.7
Family history of CAD (%) 59 61 60 0.9
History of smoking (%) 59 62 56 0.3
History of stroke (%) 6.6 9.3 7.9 0.6
Peripheral vascular disease (%) 16 15 17 0.8
Prior MI (%) 50 46 48 0.7
Prior bypass surgery (%) 22 18 19 0.6
Prior PCI (%) 31 28 25 0.2
Left ventricular ejection fraction (%) 49  12 48  13 49  12 0.7
Lesions n  120 n  562 n  327
Target vessel
Left main artery (%) 3.3 2 2.7 0.5
Left anterior descending (%) 39 39 38 0.9
Left circumflex (%) 20 21 20 0.9
Right coronary (%) 38 38 39 0.9
Lesion characteristics
Ostial location (%) 6.3 7.4 6.8 0.4
Bifurcation lesion (%) 5.8 8.9 7.7 0.1
Thrombus (%) 2.4 3.8 2.9 0.7
TIMI 0–2 (%) 9.2 9.4 9 0.8
CAD  coronary artery disease; MI  myocardial infarction; PCI  percutaneous coronary intervention; TIMI 
Thrombolysis In Myocardial Infarction.
Abbreviations and Acronyms
CK-MB  creatine kinase-MB isoenzyme
CSA  cross-sectional area
EEM  external elastic membrane
IVUS  intravascular ultrasound
MACE  multiple adverse cardiac events
MI  myocardial infarction
PCI  percutaneous coronary intervention
TLR  target lesion revascularization
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selected. If the plaque was “packed” around the catheter, the
lumen was assumed to be the physical (not acoustical) size of
the catheter. Because IVUS cannot measure media thick-
ness accurately, plaque and media were the measure of
plaque mass. Cross-sectional narrowing (plaque and media
CSA divided by EEM CSA) has also been called the plaque
burden or percent plaque area. The reference segment
averaged the most visually normal cross-sections (largest
lumen with least plaque) within 10 mm proximal and distal
to the lesion but between major branches; a distal reference
was used for ostial lesions. Percent stent expansion was
measured as final stent CSA divided by the average of the
proximal and distal reference lumen CSA. These IVUS
methods have been validated and published previously
(15,16).
Clinical definitions and follow-up. Pre-specified clinical
and laboratory demographic information was obtained from
hospital charts that were reviewed by independent research
personnel who were unaware of the objectives of the study;
data were entered prospectively into a database. Standard
definitions included: 1) Q-wave MI—the presence of new
pathologic Q-waves associated with an elevation of CK or
CK-MB at least two times the upper normal value and
2) non–Q-wave MI—CK-MB elevation at least five times
the upper normal value without new Q-waves.
CK-MB levels were systematically evaluated before in-
tervention and at 6 h and 24 h after the procedure. If
CK-MB levels were elevated, serial measurements were
performed every 8 h and the peak level was recorded. All
CK-MB determinations were performed in the clinical
chemistry laboratory by the mass-determination method
(normal range 0 to 4 ng/ml). For this study, only the peak
CK-MB values post-PCI were used.
One-year clinical follow-up was performed by either
telephone contact or office visit. Multiple adverse cardiac
events (MACE) were recorded, including death (all-cause),
Q-wave MI, and target lesion revascularization (TLR)
(whether PCI or surgical). These data collection methods
have been published previously (17).
Statistical analysis. Statistical analysis was performed us-
ing SAS (Statistical Analysis Systems, SAS Institute Inc,
Cary, North Carolina) by a dedicated data analysis center.
Continuous variables are expressed as mean  1 SD and
categorical variables as frequency (%). Continuous variables
were compared using analysis of variance or the unpaired
Student t test. Categorical variables were compared with
chi-squared statistics. A p value 0.05 was considered
statistically significant.
RESULTS
Baseline patient and lesion characteristics were similar
among the three groups, except from a higher percentage of
men in Group 2, as shown in Table 1. There were no
significant differences in high-risk lesion characteristics such
as ostial location, bifurcation, thrombus, and Thrombolysis
in Myocardial Infarction 0 to 2 flow among the three
groups.
Procedural data and quantitative coronary angiography.
As shown in Table 2, angiographic reference was larger and
lesion length was longer in Group 1. Atheroablation use was
more frequent in Group 1, and the balloon-to-artery ratio
was greater in Group 3. There were no other statistically
significant differences among the three groups regarding
procedural data and complications.
Table 2. Procedural Data and Quantitative Coronary Angiographic Analysis
Stent Expansion Ratio
Group 1
<70%
Group 2
70%–100%
Group 3
>100% p Value
Angiographic data
Lesion length (mm) 14.84  10.25 11.14  7.43 10.25  6.60 0.0008
Reference vessel diameter (mm) 3.08  0.44 2.91  0.57 2.86  0.50 0.04
Pre-PCI MLD (mm) 1.07  0.57 0.98  0.47 1.00  0.53 0.5
Pre-PCI DS (%) 64  21 66  15 65  18 0.7
Post-PCI MLD (mm) 2.83  0.57 2.73  0.58 2.73  0.64 0.5
Post-PCI DS (%) 12  16 9  16 10  15 0.6
Procedural data
Stent diameter (mm) 3.48  0.44 3.46  0.41 3.49  0.44 0.3
Maximum balloon diameter (mm) 3.59  0.62 3.51  0.49 3.51  0.48 0.3
Maximum balloon inflation (atm) 15.04  3.85 15.28  3.41 15.02  3.34 0.6
Balloon-to-artery ratio 1.19  0.23 1.23  0.22 1.27  0.21 0.01
Stents per lesion 1.23  0.45 1.28  0.54 1.25  0.56 0.4
Atheroablation (%) 30 23 21 0.04
Glycoprotein IIb/IIIa inhibitors (%) 0.8 4.8 3.4 1.0
Procedure time (sc) 77  69 75  42 74  52 0.6
Bailout stenting (%) 19 21 17 0.1
Procedural complications
Thrombus (%) 0.7 0.8 1.0 0.8
Perforation (%) 0.2 0 0.3 1.0
Abrupt closure (%) 0.8 0 0.6 0.1
DS  diameter stenosis; MLD  minimal luminal diameter; PCI  percutaneous coronary intervention.
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IVUS analysis. Intravascular ultrasound findings are
shown in Table 3. Group 1 had larger proximal reference
EEMs, lumen CSAs, distal reference EEMs, pre-
intervention EEMs, and plaque and media CSAs at the
lesion site. However, there were no statistically significant
differences regarding pre-PCI arc of calcium, lumen CSA,
minimal lumen diameter, CSA, and cross-sectional narrow-
ing among the groups. Post-stent implantation, Group 3
had larger lumen dimensions than the other two groups.
In-hospital outcome. Procedural success was 98% to 99%
in all the groups. Table 4 summarizes the major in-hospital
complications. There were no statistically significant differ-
ences among the three groups. Group 3 patients had a
higher CK-MB release rate than the other two groups,
regardless of the level of CK-MB elevation examined
(Fig. 1).
Clinical follow-up. Cumulative clinical events at one-year
follow-up are shown in Figure 2. There were no statistically
significant differences regarding death or Q-wave MI
among the three groups. However, Group 3 patients had
lower TLR and MACE rates than the other groups (p 
0.04 and 0.01 respectively). In addition, there was a trend
toward lower mortality in Group 3 (9% vs. 4.4% vs. 4.0%,
p  0.07). Figure 3 displays one-year TLR according to
percent stent expansion. Higher percent stent expansion
(90%) resulted in significantly lower TLR at one year
compared with lower stent expansion (90%).
DISCUSSION
The main finding of the current study is that stent overex-
pansion is accompanied by significantly lower TLR and
MACE rate at one year, but at the expense of a higher
post-PCI CK-MB elevation.
Relatively low-level release of cardiac enzymes occurs
after 6% to 30% of otherwise successful PCIs (6–8). It has
also been shown that elevation of CK-MB is associated with
increased late mortality (6,18–21). However, the impact of
CK-MB release on clinical outcome is rather small in the
absence of new Q-waves or elevation less than eight times
the upper limit of normal (20,22–24). It has also been
suggested that a larger post-PCI lumen dimension, attained
after successful new device PCI, primarily determines sub-
sequent cardiac events and is associated with lower TLR
Table 4. In-Hospital Events
Stent Expansion Ratio
Group 1 Group 2 Group 3
p Value<70% 70%–100% >100%
Death (%) 0.8 0.4 0 0.2
Q-wave MI (%) 0 0.2 0.3 1.0
Stroke (%) 0.8 0 0.3 0.1
Emergency CABG (%) 0 0.4 0 0.6
Repeat PCI (%) 0.8 1.2 1.2 1.0
CABG  coronary artery bypass grafting; MI  myocardial infarction; PCI 
percutaneous coronary intervention.
Table 3. Intravascular Ultrasound Findings
Stent Expansion Ratio
Group 1
<70%
Group 2
70%–100%
Group 3
>100% p Value
Proximal reference
EEM CSA (mm2) 18.23  6.06 16.24  5.42 14.79  4.49 0.0001
Lumen CSA (mm2) 10.98  5.00 8.99  2.76 7.66  2.41 0.0001
Distal reference
EEM CSA (mm2) 13.81  6.65 12.95  4.64 12.30  4.07 0.09
Lumen CSA (mm2) 9.20  4.83 7.93  2.91 6.85  2.41 0.0001
Lesion pre-intervention
Arc of calcium 113  102 106  99 109  97 0.9
EEM CSA (mm2) 18.06  26.39 13.95  4.90 13.04  6.25 0.02
Lumen CSA (mm2) 2.23  1.22 2.20  1.30 2.05  1.27 0.1
MLD (mm) 1.46  0.36 1.45  0.40 1.39  0.36 0.1
Plaque and media CSA (mm2) 15.92  26.33 11.71  4.75 10.98  6.21 0.002
CSN (%) 80  31 83  10 83  11 0.2
Lesion post-intervention
Lumen CSA (mm2) 5.98  2.32 7.26  2.16 8.25  2.25 0.0001
MLD (mm) 2.50  0.52 2.78  0.45 2.97  0.44 0.0001
CSA  cross-sectional area; CSN  cross-sectional narrowing; EEM  external elastic membrane; MLD  minimal lumen
diameter.
Figure 1. Creatine kinase-MB isoenzyme elevation (CK-MB) post percu-
taneous coronary intervention according to stent expansion. CK-MB
release one to three times normal was similar in Group 1 (stent expansion
70%) vs. Group 2 (stent expansion 70% to 100%) vs. Group 3 (stent
expansion 100%). However, there was a stepwise increase in CK-MB 3
to 5 times and 5 times normal in Group 1 vs. Group 2 vs. Group 3.
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(25,26); thus, the potentially adverse influence of CK-MB
elevation may be overshadowed by the other favorable
outcomes after optimal PCI stent (22).
In the present study, the aggressive stent expansion
strategy was associated with higher CK-MB elevation post
PCI. It is of note that atheroablation was more frequent,
and plaque and media were larger, in Group 1 (least stent
expansion group). As previously reported, periprocedural
enzyme release varies markedly with different devices, being
most common with combined stenting and atheroablation
(20). We have also suggested that the increased incidence of
CK-MB elevation after stenting and atheroablation may
simply reflect the baseline presence of more diffuse athero-
sclerotic disease and greater plaque burden (5).
Stent overexpansion had been considered elsewhere to
result in an increased late loss or even higher restenosis rates
(27). Indeed, we documented potentially greater vessel wall
trauma, as suggested by the greater balloon-to-artery ratio
in Group 3; however, this finding was not associated with an
increased rate of late events. To the contrary, increased stent
expansion correlated with reduced one-year event rates and,
in particular, an arithmetically lower one-year mortality.
This finding is in accordance with studies in which stent
overexpansion resulted in larger final lumen dimensions that
were maintained at follow-up, despite greater lumen loss
due to exaggerated intimal hyperplasia in response to the
greater vessel wall trauma (28,29).
It is of note that Group 1 lesions were longer than lesions
in the other two groups. Conversely, Group 3 vessels were
smaller, as suggested by the smaller EEM CSA. Longer
lesion length and smaller vessel size are well-recognized risk
factors for in-stent restenosis (30). There are two main
determinants of the final stent CSA: vessel size and implan-
tation technique (30). Intravascular ultrasound guidance can
be used to optimize final stent implantation results, mainly
because of bigger balloons (greater balloon-to-artery ratio,
as seen in this study) or higher inflation pressures (30,31).
After IVUS-guided overdilation, minimal stent lumen CSA
and diameter have been shown to increase by as much as
11% to 80% (16,29,32). In the present study, we examined
various IVUS-derived stent expansion cutoff values in rela-
tion to clinical restenosis and found that percent stent
expansion 90% had the lowest one-year TLR rate.
Limitations. First, this was a retrospective analysis; in an
attempt to offset this limitation, the data were collected
prospectively by independent monitors and entered into a
dedicated database, and independent laboratories inter-
preted all angiographic and IVUS studies. Second, complete
follow-up was available in 92% of the whole patient popu-
lation (89%, 92%, and 93% for Groups 1, 2, and 3,
respectively). We did not use more sensitive markers of
myocardial damage such as troponin T or I tests. However,
Figure 2. One-year cumulative outcome. There was a stepwise decrease in
death, multiple adverse cardiac events, and target lesion revascularization in
Group 1 (stent expansion 70%) vs. Group 2 (stent expansion 70% to
100%) vs. Group 3 (stent expansion 100%). MACE  multiple adverse
cardiac events; Q-W MI  Q-wave myocardial infarction; TLR  target
lesion revascularization.
Figure 3. The occurrence of any target lesion revascularization event decreased with increasing percent stent expansion (% stent expansion  final stent
CSA/[proximal CSA  distal CSA]/2). CSA  cross-sectional area.
1904 Iakovou et al. JACC Vol. 42, No. 11, 2003
Stent Expansion, CK-MB, and Clinical Restenosis December 3, 2003:1900–5
measurement of CK-MB release is an accepted, widely used
method of assessment of myocardial injury after PCI, used
in a large number of previous studies (5,8,9,18,22). In
addition, we do not report data on time of ischemia and
information about side branch occlusion. Nevertheless, the
absence of reporting these data does not alter the basic
hypothesis of the current study.
Conclusions. Stent overexpansion (final lumen greater
than reference lumen CSA) is accompanied by a higher
periprocedural CK-MB release but a lower TLR and a trend
toward lower mortality at one year. Increased periprocedural
CK-MB release appears as a trade-off for optimal stent
implantation and lower clinical restenosis and one-year
MACE.
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